Optimal Combination of Doses for Isoniazid and Vitamin B6 to Treat Tuberculosis Destructive Guinea Pigs
International Journal of Animal Science and Technology
Volume 1, Issue 1, December 2017, Pages: 1-4
Received: Oct. 28, 2017; Accepted: Nov. 14, 2017; Published: Dec. 1, 2017
Views 935      Downloads 72
Authors
Ludmila Gayova, Department of Bioorganic and Biological Chemistry, Bogomolets National Medical University, Kyiv, Ukraine
Vasil Petrenko, Department of Phthisiology and Pulmonology, Bogomolets National Medical University, Kyiv, Ukraine
Yulia Kuharivska, Department of Phthisiology and Pulmonology, Bogomolets National Medical University, Kyiv, Ukraine
Serhiy Baran, Department of Bioorganic and Biological Chemistry, Bogomolets National Medical University, Kyiv, Ukraine
Article Tools
Follow on us
Abstract
This paper presents the results of morphological studies of tuberculosis and nonspecific inflammatory changes of the guinea pigs in the treatment of different ratios of isoniazid with pyridoxine hydrochloride. The optimal dose ratio of the expression of specific and non-specific manifestations of inflammation in the lungs, liver, kidneys and spleen. Also prayed to interpret the results of studies for the treatment of destructive tuberculosis in humans. It was proposed a method of determining the optimum ratio of doses of the most pronounced therapeutic effect and minimal side effects. The aim of the study was to conduct morphological evaluation of lesions of internal organs (lungs, liver, kidneys, spleen) after treatment of experimental tuberculosis of guinea pigs different ratios of doses of isoniazid and pyridoxine hydrochloride. The optimal therapeutic effect is obtained by treating animals with experimental tuberculosis isoniazid at a dose of 26 mg/kg of vitamin B6 and 10mg/kg body weight of the animal, thus completely disappeared phenomenon specific inflammation in the lungs, liver, kidneys and spleen. This phenomenon also disappeared perifocal nonspecific inflammation. Disappeared dystrophic and necrotic changes in the studied organs.
Keywords
Tuberculosis, Experimental Model, Guinea Pigs, Isoniazid, Vitamin B6, Optimal Ratio
To cite this article
Ludmila Gayova, Vasil Petrenko, Yulia Kuharivska, Serhiy Baran, Optimal Combination of Doses for Isoniazid and Vitamin B6 to Treat Tuberculosis Destructive Guinea Pigs, International Journal of Animal Science and Technology. Vol. 1, No. 1, 2017, pp. 1-4. doi: 10.11648/j.ijast.20170101.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Nizova NM, et al. Tuberkuloz v Ukrayini: analityko-statystychnyy dovidnyk (Tuberculosis in Ukraine: analytical and statistical reference book). Kyiv: Blank-Pres. 2015; 142 p.
[2]
Petrenko VI, Protsyuk RG. Problema tuberkulozu v Ukrayini (The problem of tuberculosis in Ukraine). Tuberkuloz, legenevi khvoroby, VIL-infektsiya. 2015; No 2(21): 16–29.
[3]
Smith DW, Harding GE. Animal model of human disease. Pulmonary tuberculosis. Animal model: Experimental airborne tuberculosis in the guinea pig. Am J Pathol. 1977; 89: 273–276.
[4]
World Health Organization. Global tuberculosis Control report. WHO report. Geneva, Switzerland. 2012: 273 p.
[5]
Riley RL, Mills CC, Nyka W, Weinstock N, Storey PB, Sultan LU, Riley MC, Wells WF. Aerial dissemination of pulmonary tuberculosis: a two- year study of contagion in a tuberculosis ward. Am J Hyg 1959; 70: 2.
[6]
McMurray DN. Guinea pig model of tuberculosis. In: Bloom BR, editor. Tuberculosis: pathogenesis, protection and control. Washington, DC: American Society for Microbiology; 1994. pp. 135–147.
[7]
Effect of Chemical Adjuvants on High Doses of Streptomycin and of Isoniazid in Laboratory Animals 1, 2 American Review of Respiratory Disease, 87(5), pp. 717-725.
[8]
Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2008.402.
[9]
Waikhom R, Sarkar D, Bennikal M, Pandey R. Rapidly progressive glomerulonephritis in tuberculosis. Saudi J Kidney Dis Transpl. 2014; 25: 872–5. doi: 10.4103/1319-2442.135187.
[10]
Keven K, Ulger FA, Oztas E, Ergün I, Ekmekçi Y, Ensari A, et al. A case of pulmonary tuberculosis associated with IgA nephropathy. Int J Tuberc Lung Dis. 2004; 8: 1274–5.
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-688-8931